Percutaneous transluminal therapy of occluded saphenous vein grafts

Can the challenge be met with ultrasound thrombolysis?

Uri Rosenschein, Georg Gaul, Raimund Erbel, Franz Amann, Diego Velasguez, H. Stoerger, Ruediger Simon, German Gomez, Joerg Troster, Antonio Bartorelli, Michael Pieper, Zenon Kyriakides, Shlomo Laniado, Hylton I. Miller, Alain Cribier, Jean Fajadet

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background - Percutaneous transluminal treatment of a thrombotic vein graft yields poor results. We have previously reported our experience with transluminal percutaneous coronary ultrasound thrombolysis (CUT) in the setting of acute myocardial infarction (AMI). This report describes the first experience with ultrasound thrombolysis in thrombus-rich lesions in saphenous vein grafts (SVGs), most of which were occluded. Methods and Results - The patients (n=20) were mostly male (85%), aged 64±4 years old. The presenting symptom was AMI in 2 patients (10%) and unstable angina in the rest. Fifteen patients (75%) had totally occluded SVGs. The median age of clots was 6 days (range, 0 to 100 days). The ultrasound thrombolysis device has a 1.6-mm-long tip and fits into a 7F guiding catheter over a 0.014-in guidewire in a 'rapid-exchange' system. CUT (41 kHz, 1.8 W, ≤6 minutes) led to device success in 14 (70%) of the patients and residual stenosis of 65±28%. Procedural success was obtained in 13 (65%) of the patients, with a final residual stenosis of 5±8%. There was a low rate of device-related adverse events: 1 patient (5%) had a non-Q-wave myocardial infarction, and distal embolization was noted in 1 patient (5%). Adjunct PTCA or stenting was used in all patients. There were no serious adverse events during hospitalization. Conclusions - Ultrasound thrombolysis in thrombus-rich lesions in SVGs offers a very promising therapeutic option.

Original languageEnglish
Pages (from-to)26-29
Number of pages4
JournalCirculation
Volume99
Issue number1
Publication statusPublished - Jan 5 1999

Fingerprint

Saphenous Vein
Transplants
Myocardial Infarction
Therapeutics
Equipment and Supplies
Pathologic Constriction
Thrombosis
Unstable Angina
Veins
Hospitalization
Catheters

Keywords

  • Bypass
  • Grafting
  • Occlusion
  • Thrombolysis
  • Ultrasonics

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Rosenschein, U., Gaul, G., Erbel, R., Amann, F., Velasguez, D., Stoerger, H., ... Fajadet, J. (1999). Percutaneous transluminal therapy of occluded saphenous vein grafts: Can the challenge be met with ultrasound thrombolysis? Circulation, 99(1), 26-29.

Percutaneous transluminal therapy of occluded saphenous vein grafts : Can the challenge be met with ultrasound thrombolysis? / Rosenschein, Uri; Gaul, Georg; Erbel, Raimund; Amann, Franz; Velasguez, Diego; Stoerger, H.; Simon, Ruediger; Gomez, German; Troster, Joerg; Bartorelli, Antonio; Pieper, Michael; Kyriakides, Zenon; Laniado, Shlomo; Miller, Hylton I.; Cribier, Alain; Fajadet, Jean.

In: Circulation, Vol. 99, No. 1, 05.01.1999, p. 26-29.

Research output: Contribution to journalArticle

Rosenschein, U, Gaul, G, Erbel, R, Amann, F, Velasguez, D, Stoerger, H, Simon, R, Gomez, G, Troster, J, Bartorelli, A, Pieper, M, Kyriakides, Z, Laniado, S, Miller, HI, Cribier, A & Fajadet, J 1999, 'Percutaneous transluminal therapy of occluded saphenous vein grafts: Can the challenge be met with ultrasound thrombolysis?', Circulation, vol. 99, no. 1, pp. 26-29.
Rosenschein U, Gaul G, Erbel R, Amann F, Velasguez D, Stoerger H et al. Percutaneous transluminal therapy of occluded saphenous vein grafts: Can the challenge be met with ultrasound thrombolysis? Circulation. 1999 Jan 5;99(1):26-29.
Rosenschein, Uri ; Gaul, Georg ; Erbel, Raimund ; Amann, Franz ; Velasguez, Diego ; Stoerger, H. ; Simon, Ruediger ; Gomez, German ; Troster, Joerg ; Bartorelli, Antonio ; Pieper, Michael ; Kyriakides, Zenon ; Laniado, Shlomo ; Miller, Hylton I. ; Cribier, Alain ; Fajadet, Jean. / Percutaneous transluminal therapy of occluded saphenous vein grafts : Can the challenge be met with ultrasound thrombolysis?. In: Circulation. 1999 ; Vol. 99, No. 1. pp. 26-29.
@article{3dd19108cb2f4d6bac6f678b0acf417c,
title = "Percutaneous transluminal therapy of occluded saphenous vein grafts: Can the challenge be met with ultrasound thrombolysis?",
abstract = "Background - Percutaneous transluminal treatment of a thrombotic vein graft yields poor results. We have previously reported our experience with transluminal percutaneous coronary ultrasound thrombolysis (CUT) in the setting of acute myocardial infarction (AMI). This report describes the first experience with ultrasound thrombolysis in thrombus-rich lesions in saphenous vein grafts (SVGs), most of which were occluded. Methods and Results - The patients (n=20) were mostly male (85{\%}), aged 64±4 years old. The presenting symptom was AMI in 2 patients (10{\%}) and unstable angina in the rest. Fifteen patients (75{\%}) had totally occluded SVGs. The median age of clots was 6 days (range, 0 to 100 days). The ultrasound thrombolysis device has a 1.6-mm-long tip and fits into a 7F guiding catheter over a 0.014-in guidewire in a 'rapid-exchange' system. CUT (41 kHz, 1.8 W, ≤6 minutes) led to device success in 14 (70{\%}) of the patients and residual stenosis of 65±28{\%}. Procedural success was obtained in 13 (65{\%}) of the patients, with a final residual stenosis of 5±8{\%}. There was a low rate of device-related adverse events: 1 patient (5{\%}) had a non-Q-wave myocardial infarction, and distal embolization was noted in 1 patient (5{\%}). Adjunct PTCA or stenting was used in all patients. There were no serious adverse events during hospitalization. Conclusions - Ultrasound thrombolysis in thrombus-rich lesions in SVGs offers a very promising therapeutic option.",
keywords = "Bypass, Grafting, Occlusion, Thrombolysis, Ultrasonics",
author = "Uri Rosenschein and Georg Gaul and Raimund Erbel and Franz Amann and Diego Velasguez and H. Stoerger and Ruediger Simon and German Gomez and Joerg Troster and Antonio Bartorelli and Michael Pieper and Zenon Kyriakides and Shlomo Laniado and Miller, {Hylton I.} and Alain Cribier and Jean Fajadet",
year = "1999",
month = "1",
day = "5",
language = "English",
volume = "99",
pages = "26--29",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Percutaneous transluminal therapy of occluded saphenous vein grafts

T2 - Can the challenge be met with ultrasound thrombolysis?

AU - Rosenschein, Uri

AU - Gaul, Georg

AU - Erbel, Raimund

AU - Amann, Franz

AU - Velasguez, Diego

AU - Stoerger, H.

AU - Simon, Ruediger

AU - Gomez, German

AU - Troster, Joerg

AU - Bartorelli, Antonio

AU - Pieper, Michael

AU - Kyriakides, Zenon

AU - Laniado, Shlomo

AU - Miller, Hylton I.

AU - Cribier, Alain

AU - Fajadet, Jean

PY - 1999/1/5

Y1 - 1999/1/5

N2 - Background - Percutaneous transluminal treatment of a thrombotic vein graft yields poor results. We have previously reported our experience with transluminal percutaneous coronary ultrasound thrombolysis (CUT) in the setting of acute myocardial infarction (AMI). This report describes the first experience with ultrasound thrombolysis in thrombus-rich lesions in saphenous vein grafts (SVGs), most of which were occluded. Methods and Results - The patients (n=20) were mostly male (85%), aged 64±4 years old. The presenting symptom was AMI in 2 patients (10%) and unstable angina in the rest. Fifteen patients (75%) had totally occluded SVGs. The median age of clots was 6 days (range, 0 to 100 days). The ultrasound thrombolysis device has a 1.6-mm-long tip and fits into a 7F guiding catheter over a 0.014-in guidewire in a 'rapid-exchange' system. CUT (41 kHz, 1.8 W, ≤6 minutes) led to device success in 14 (70%) of the patients and residual stenosis of 65±28%. Procedural success was obtained in 13 (65%) of the patients, with a final residual stenosis of 5±8%. There was a low rate of device-related adverse events: 1 patient (5%) had a non-Q-wave myocardial infarction, and distal embolization was noted in 1 patient (5%). Adjunct PTCA or stenting was used in all patients. There were no serious adverse events during hospitalization. Conclusions - Ultrasound thrombolysis in thrombus-rich lesions in SVGs offers a very promising therapeutic option.

AB - Background - Percutaneous transluminal treatment of a thrombotic vein graft yields poor results. We have previously reported our experience with transluminal percutaneous coronary ultrasound thrombolysis (CUT) in the setting of acute myocardial infarction (AMI). This report describes the first experience with ultrasound thrombolysis in thrombus-rich lesions in saphenous vein grafts (SVGs), most of which were occluded. Methods and Results - The patients (n=20) were mostly male (85%), aged 64±4 years old. The presenting symptom was AMI in 2 patients (10%) and unstable angina in the rest. Fifteen patients (75%) had totally occluded SVGs. The median age of clots was 6 days (range, 0 to 100 days). The ultrasound thrombolysis device has a 1.6-mm-long tip and fits into a 7F guiding catheter over a 0.014-in guidewire in a 'rapid-exchange' system. CUT (41 kHz, 1.8 W, ≤6 minutes) led to device success in 14 (70%) of the patients and residual stenosis of 65±28%. Procedural success was obtained in 13 (65%) of the patients, with a final residual stenosis of 5±8%. There was a low rate of device-related adverse events: 1 patient (5%) had a non-Q-wave myocardial infarction, and distal embolization was noted in 1 patient (5%). Adjunct PTCA or stenting was used in all patients. There were no serious adverse events during hospitalization. Conclusions - Ultrasound thrombolysis in thrombus-rich lesions in SVGs offers a very promising therapeutic option.

KW - Bypass

KW - Grafting

KW - Occlusion

KW - Thrombolysis

KW - Ultrasonics

UR - http://www.scopus.com/inward/record.url?scp=0033547824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033547824&partnerID=8YFLogxK

M3 - Article

VL - 99

SP - 26

EP - 29

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 1

ER -